Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy

TY - JOUR

T1 - Long-term remission in multiply relapsed enteropathy-associated T-cell lymphoma following CD30 CAR T-cell therapy

AU - Voorhees, Timothy J.

AU - Ghosh, Nilanjan

AU - Grover, Natalie

AU - Block, Jared

AU - Cheng, Catherine

AU - Morrison, Kaitlin

AU - Ivanova, Anastasia

AU - Dotti, Gianpietro

AU - Serody, Jonathan

AU - Savoldo, Barbara

AU - Beaven, Anne W.

N1 - Funding Information: Conflict-of-interest disclosure: Competing interests of authors from the University of North Carolina are managed in accordance with institutional policies. B.S., G.D., and J.S. have a pending patent concerning the CD30 CAR-T product presented in this article. J.S. has filed an intellectual property patent regarding the use of STING agonists to enhance CAR T-cell therapy. N. Grover served as a consultant for Tessa Therapeutics, has received research funding from Genentech, and has served on an advisory board for Kite Pharma. T.J.V. received research funding from AstraZeneca. The University of North Carolina has a research collaboration with Tessa Therapeutics. The remaining authors declare no competing financial interests. Funding Information: Acknowledgments This work was supported by a grant from the National Heart, Lung, and Blood Institute, National Institutes of Health (RO1HL114564) (B.S.), by the University Cancer Research Fund at the Lineberger Comprehensive Cancer Center (B.S. and G.D.), and by a grant from Stand Up To Cancer (7000000853) (G.D.).

PY - 2020/12/8

Y1 - 2020/12/8

UR - https://www.scopus.com/pages/publications/85098067140

U2 - 10.1182/bloodadvances.2020003218

DO - 10.1182/bloodadvances.2020003218

M3 - Article

C2 - 33259598

AN - SCOPUS:85098067140

SN - 2473-9529

VL - 4

SP - 5925

EP - 5928

JO - Blood Advances

JF - Blood Advances

IS - 23

ER -